Ajanta Pharma on January 31 reported a consolidated net profit of Rs 210 crore for the October-December quarter, up 56 percent over last year's Rs 135 crore.
The Mumbai-based pharma major's revenue came in at Rs 1,105 crore, up 14 percent from Rs 972 crore a year back.
The company's earnings before interest, taxes, depreciation and amortisation (EBITDA) were at Rs 314 crore, up 85 percent from Rs 170 crore in the year-ago period.
The Board of Directors have approved a second interim dividend of Rs 26 per share for the FY2024. "Each share of Rs 2 face value will receive a dividend of Rs. 26, amounting to the divided amount of Rs 327 crore," the regulatory filing stated.
According to Ajanta, Rs 308 crore of its total revenue came from India branded generics in the reported quarter and US generics business gave a revenue of Rs 252 crore.
The company spent Rs 52 crore on R&D expenditure in this quarter, which is 5 percent of its revenues.
Shares of the company settled at Rs 2,168.40 apiece on the BSE during the day's trading session, up 2.69 percent from previous day's close.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
